Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2&agr; antagonists
    61.
    发明授权
    Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2&agr; antagonists 有权
    亚麻基7-氧杂双环[2.2.1]庚烷恶唑作为前列腺素F2α拮抗剂

    公开(公告)号:US06509364B2

    公开(公告)日:2003-01-21

    申请号:US10087547

    申请日:2002-02-28

    IPC分类号: C07D41310

    CPC分类号: C07D493/08

    摘要: The present invention provides novel compounds represented by the general formula I. and pharmaceutically acceptable salts thereof wherein m, n, X, R, R1 and R2 are as defined in the specification. The novel compounds are PGF2&agr; antagonists, useful in pharmaceutical compositions for treating PGF2&agr;-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

    摘要翻译: 本发明提供由通式I表示的新化合物及其药学上可接受的盐,其中m,n,X,R 1,R 2和R 2如说明书中所定义。 新型化合物是PGF2α拮抗剂,可用于治疗PGF2α介导的疾病反应的药物组合物,例如与类风湿性关节炎和牛皮癣相关的炎性反应,生殖障碍,支气管收缩性疾病(哮喘),过度骨分解(骨质疏松症),消化性溃疡,心脏病 ,血小板聚集和血栓形成。

    Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    64.
    发明授权
    Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents 有权
    环戊烷庚烷(ENE)OIC酸,2-杂芳基烯基衍生物作为治疗剂

    公开(公告)号:US08168680B2

    公开(公告)日:2012-05-01

    申请号:US13023257

    申请日:2011-02-08

    IPC分类号: A61K31/5575 C07C405/00

    CPC分类号: C07C405/00 C07D333/28

    摘要: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

    摘要翻译: 公开了具有本文详细描述的基团的化合物或其药学上可接受的盐或其前药。 本文还公开了包含其衍生物或其衍生物的化合物或其结构或衍生物的化合物的药学上可接受的盐,四唑或前药,所述衍生物在此详细描述。 本文还公开了治疗疾病或病症的方法,包括青光眼和眼内压升高。 还公开了与其相关的药物制备的组合物和方法。

    Therapeutic compounds
    65.
    发明授权
    Therapeutic compounds 有权
    治疗化合物

    公开(公告)号:US07964599B2

    公开(公告)日:2011-06-21

    申请号:US12434008

    申请日:2009-05-01

    IPC分类号: A61K31/535 C07D295/18

    CPC分类号: C07D295/088

    摘要: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.

    摘要翻译: 公开了包含其药学上可接受的盐或其前药的化合物,其中J,B,Y和A如上所述。 还公开了与之相关的方法,组合物和药物。

    CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
    66.
    发明申请
    CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS 有权
    环丙沙星(ENE)OIC酸,作为治疗剂的2-异亮氨酸衍生物

    公开(公告)号:US20110130439A1

    公开(公告)日:2011-06-02

    申请号:US13023257

    申请日:2011-02-08

    CPC分类号: C07C405/00 C07D333/28

    摘要: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein.Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

    摘要翻译: 公开了具有本文详细描述的基团的化合物或其药学上可接受的盐或其前药。 本文还公开了包含其衍生物或其衍生物的化合物或其结构或衍生物的化合物的药学上可接受的盐,四唑或前药,所述衍生物在此详细描述。 本文还公开了治疗疾病或病症的方法,包括青光眼和眼内压升高。 还公开了与其相关的药物制备的组合物和方法。

    THERAPEUTIC COMPOUNDS
    67.
    发明申请
    THERAPEUTIC COMPOUNDS 有权
    治疗化合物

    公开(公告)号:US20100317872A1

    公开(公告)日:2010-12-16

    申请号:US12860518

    申请日:2010-08-20

    IPC分类号: C07D409/06

    摘要: A compound having a substituted five or six-membered carbocycle or heterocycle directly bonded to a substituted aryl or heteroaryl ring, wherein said compound has an EC50 value of 20 nM or less at the prostaglandin EP2 receptor according to the cAMP assay.Methods, compositions, and medicaments related thereto are also disclosed.

    摘要翻译: 具有与取代的芳基或杂芳基环直接结合的取代的五元或六元碳环或杂环的化合物,其中所述化合物根据cAMP测定在前列腺素EP2受体的EC 50值为20nM以下。 还公开了与之相关的方法,组合物和药物。

    10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
    69.
    发明授权
    10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists 有权
    10-羟基-11-二氢前列腺素类似物作为选择性EP4激动剂

    公开(公告)号:US07652063B2

    公开(公告)日:2010-01-26

    申请号:US11532404

    申请日:2006-09-15

    申请人: Yariv Donde

    发明人: Yariv Donde

    CPC分类号: C07D333/62

    摘要: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, wherein the dashed line represents the presence or absence of a double bond; J is C═O or CHOH; A is —(CH2)6—, or cis —CH2CH═CH—(CH2)3—, wherein 1 or 2 carbons may be substituted with S or O; B is CO2H, or CO2R, CONR2, CONHCH2CH2OH, CON(CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2, or R is H, C1-6 alkyl; D is —(CH2)n—, —X(CH2)n, or —(CH2)nX—, wherein n is from 0 to 3 and X is S or O; and E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms is disclosed herein. Methods, compositions, and medicaments related thereto, as well as experimental results showing prostaglandin EP4 selective agonist activity for certain compounds disclosed herein, are also disclosed.

    摘要翻译: 包含或其药学上可接受的盐或其前药的化合物,其中虚线表示双键的存在或不存在; J为C-O或CHOH; A是 - (CH 2)6 - 或顺式-CH 2 CH-CH-(CH 2)3 - ,其中1或2个碳可以被S或O取代; B是CO 2 H或CO 2 R,CONR 2,CONHCH 2 CH 2 OH,CON(CH 2 CH 2 OH)2,CH 2 OR,P(O)(OR)2,CONRSO 2 R,SONR 2或R是H,C 1-6烷基; D是 - (CH 2)n - , - X(CH 2)n或 - (CH 2)n X-,其中n为0至3,X为S或O; 并且E是具有0至4个取代基的芳族或杂芳族部分,所述取代基各自包含1至6个非氢原子。 还公开了与其相关的方法,组合物和药物,以及显示本文公开的某些化合物的前列腺素EP4选择性激动剂活性的实验结果。